AdAlta (ASX: 1AD) is a clinical stage biotechnology business addressing the need for effective cellular immunotherapies for the treatment of solid cancers.
Through its ‘East to West’ strategy, the Company is integrating Asia's prowess in T cell therapy development with the efficiency and quality of Australia's clinical and manufacturing ecosystem to create a pathway connecting ‘Eastern’ innovation in cellular immunotherapies with ‘Western’ regulated markets and patients.
AdAlta in-licenses products from Asian originators and invests to establish US FDA regulated manufacturing and conduct Phase I clinical studies with potential to position each product for on-licensing to larger biopharmaceutical companies for potential registrational studies and commercialization.
AdAlta implements a disciplined approach to asset selection focused on highly differentiated T cell therapy products supported by clinical data in solid cancers. The company adopts a capital efficient business model delivering a rapid return on investment in each project that is replicable and provides opportunities to scale across multiple products.
Solid tumours account for 90% of cancers yet remain underserved by current cellular immunotherapies. AdAlta aims to dominate this high-growth segment. The cellular immunotherapy market is projected to grow at a compound annual growth rate of 34% to reach US$20.3 billion by 2028.
AdAlta’s first in class fusion protein, AD-214, takes a whole new approach to fibrotic diseases of the lung and kidney, such as the degenerative and fatal Idiopathic Pulmonary Fibrosis. Following demonstration of efficacy in multiple animal models of disease and two successful Phase I clinical studies, AD-214 is available for partnering.
Why work with us
For developers of T cell immunotherapies for solid cancers across Asia we offer a fully funded pathway to globalisation of your IND-enabled or early clinical stage asset. We license highly differentiated products ready to enter clinical studies or having completed IIT or Phase 1 studies; establish and optimise manufacturing in a global reference site (in Australia) and conduct Phase 1 clinical studies under US IND, also in Australia, all at our expense. We share the proceeds of subsequent licensing deals with our partners.
For developers of drugs for fibrotic diseases, we offer AD-214, a first in class antifibrotic fusion protein that has completed Phase 1 clinical studies and is available for global out-licensing for development in lung fibrosis (IPF, etc) and kidney fibrosis (Alport Syndrome, Lupus Nephritis, etc).
For developers of infectious diseases we offer WD-34, the world's first pan strain antibody inhibitor of malaria parasite invasion (also active against Babesia and Toxoplasma spp). This asset is at lead optimisation stage. We offer co-development partnerships to develop a long acting, single dose version that could transform prophylaxis for travellers, deployed personnel and ultimately seasonal protection for pregnant women in endemic regions.
